Patients who had chronic kidney disease (CKD) coexisting with diabetes are at increased risk of developing atherosclerotic cardiovascular disease (ASCVD). Antiplatelet drug was associated with lower vascular risk in patients with diabetes, but its benefit is counterbalanced by increased bleeding. In patients with chronic kidney disease, antiplatelet drug increased the risk of cardiovascular events according to observational studies. The purpose of this study is to evaluate the benefit and safety of antiplatelet drugs for primary prevention in patients with type 2 diabetes and CKD.Post-contrast acute kidney injury (PC-AKI) is defined as an increase in serum creatinine (sCr) ≥ 0.3 mg/dL (26.5 μmol/l) or ≥ 1.5 times baseline occurring within 48−72 h of intravascular administration of iodinated contrast media, most commonly by the performance of a contrast-enhanced CT scan.

Although PC-AKI is a condition always present in the minds of both referring physicians and radiologists, recent retrospective studies have suggested that the risk of PC-AKI after intravenous (i.v.) iodinated contrast media may have been overestimated. Pre-existing chronic kidney disease (CKD) is the most critical patient-related PC-AKI risk factor. Traditional non-renal risk factors such as diabetes, hypertension, cardiovascular disease, and nephrotoxic medications are now considered non-specific risk factors for PC-AKI.

visit for more articles at  Journal of Clinical & Experimental Nephrology

Kindly submit your article at https://www.imedpub.com/submissions/clinical-experimental-nephrology.html or nephrology@eclinicalsci.com 

Regards
Mishita
Jornal co-ordinator
Journal of Clinical & Experimental Nephrology